These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 9784861)
1. Design, synthesis and biological evaluation of nonpeptide integrin antagonists. Nicolaou KC; Trujillo JI; Jandeleit B; Chibale K; Rosenfeld M; Diefenbach B; Cheresh DA; Goodman SL Bioorg Med Chem; 1998 Aug; 6(8):1185-208. PubMed ID: 9784861 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. Sheu JR; Yen MH; Kan YC; Hung WC; Chang PT; Luk HN Biochim Biophys Acta; 1997 Oct; 1336(3):445-54. PubMed ID: 9367172 [TBL] [Abstract][Full Text] [Related]
4. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Brooks PC; Montgomery AM; Rosenfeld M; Reisfeld RA; Hu T; Klier G; Cheresh DA Cell; 1994 Dec; 79(7):1157-64. PubMed ID: 7528107 [TBL] [Abstract][Full Text] [Related]
5. A novel disintegrin salmosin inhibits tumor angiogenesis. Kang IC; Lee YD; Kim DS Cancer Res; 1999 Aug; 59(15):3754-60. PubMed ID: 10446992 [TBL] [Abstract][Full Text] [Related]
6. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507 [TBL] [Abstract][Full Text] [Related]
7. Use of the 10-day-old chick embryo model for studying angiogenesis. Brooks PC; Montgomery AM; Cheresh DA Methods Mol Biol; 1999; 129():257-69. PubMed ID: 10494570 [No Abstract] [Full Text] [Related]
8. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Marcinkiewicz C; Weinreb PH; Calvete JJ; Kisiel DG; Mousa SA; Tuszynski GP; Lobb RR Cancer Res; 2003 May; 63(9):2020-3. PubMed ID: 12727812 [TBL] [Abstract][Full Text] [Related]
10. Thiophene-based vitronectin receptor antagonists. Bubenik M; Meerovitch K; Bergeron F; Attardo G; Chan L Bioorg Med Chem Lett; 2003 Feb; 13(3):503-6. PubMed ID: 12565960 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists. Lange UE; Backfisch G; Delzer J; Geneste H; Graef C; Hornberger W; Kling A; Lauterbach A; Subkowski T; Zechel C Bioorg Med Chem Lett; 2002 May; 12(10):1379-82. PubMed ID: 11992781 [TBL] [Abstract][Full Text] [Related]
12. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835 [TBL] [Abstract][Full Text] [Related]
13. [Inhibition of angiogenesis properties by SZ-21]. Sheng M; Hu XH; Ruan CG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):74-80. PubMed ID: 12667295 [TBL] [Abstract][Full Text] [Related]
14. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Yeh CH; Peng HC; Yang RS; Huang TF Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719 [TBL] [Abstract][Full Text] [Related]
15. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Ribatti D; Vacca A; Roncali L; Dammacco F Int J Dev Biol; 1996 Dec; 40(6):1189-97. PubMed ID: 9032025 [TBL] [Abstract][Full Text] [Related]
16. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. Duggan ME; Duong LT; Fisher JE; Hamill TG; Hoffman WF; Huff JR; Ihle NC; Leu CT; Nagy RM; Perkins JJ; Rodan SB; Wesolowski G; Whitman DB; Zartman AE; Rodan GA; Hartman GD J Med Chem; 2000 Oct; 43(20):3736-45. PubMed ID: 11020288 [TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) Antagonists based on a central thiophene scaffold. Peyman A; Scheunemann K; Will DW; Knolle J; Wehner V; Breipohl G; Stilz HU; Carniato D; Ruxer J; Gourvest J; Auberval M; Doucet B; Baron R; Gaillard M; Gadek TR; Bodary S Bioorg Med Chem Lett; 2001 Aug; 11(15):2011-5. PubMed ID: 11454469 [TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Oikawa T; Shimamura M Eur J Pharmacol; 1996 Dec; 318(1):93-6. PubMed ID: 9007518 [TBL] [Abstract][Full Text] [Related]
19. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Ribatti D; Nico B; Vacca A; Roncali L; Burri PH; Djonov V Anat Rec; 2001 Dec; 264(4):317-24. PubMed ID: 11745087 [TBL] [Abstract][Full Text] [Related]
20. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. Ribatti D; Gualandris A; Bastaki M; Vacca A; Iurlaro M; Roncali L; Presta M J Vasc Res; 1997; 34(6):455-63. PubMed ID: 9425998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]